Dr. Oliver Sartor on the Future of Identifying Phenotypic and Genomic Heterogeneity in mCRPC
Sartor says the test would lay out molecular data regarding a patient's malignancy and allow community oncologists to determine what would be the best course of treatment. He added that the hope for this study is to replace the "trial and error" method of treatment with something more concrete.
Oliver Sartor, MD, medical director, Tulane University, discusses a recent study in predicting effective treatments through a non-selected circulating tumor cell test. The study was presented as Abstract 163 at the 2016 ASCO GU conference in San Fransisco by first author Howard I. Scher. The abstract aims to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies for patients with metastatic castration resistant prostate cancer.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
